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Abstract
Background: Researchers often rely on trial participants to self-report clinical outcomes (for example, fractures, re-
operations). Little information exists as to the ‘accuracy’ of participant-reported clinical outcomes, particularly in
randomised controlled trials (RCTs). To help address this evidence gap, we report four case studies, nested within
different RCTs where participant-reported clinical outcome data were compared with those reported by clinicians
or extracted from medical notes.
Methods: Four publicly-funded RCTs with different methods of verifying participant-reported outcomes were
identified. In KAT, the participants were asked about hospital admissions for any reason. Where it was thought to be
relevant to the trial knee, further information was sought from the lead surgeon at the admitting site to confirm
whether or not the admission was relevant to the trial knee. In REFLUX, participants were asked about hospital
admissions for any reason. For participants who reported a re-operation, further information was sought from the
lead surgeon at the admitting site to confirm this. In RECORD, participants were asked three questions regarding
broken bones. Where low-trauma fractures were reported, clinical verification was sought, initially from the research
nurse at the site.
In CATHETER, participants were asked about urinary tract infections (UTIs), and a prescription of antibiotics was
provided for the treatment of UTIs following urethral catheterisation. The GPs of those who reported a UTI were
contacted to confirm that an antibiotic prescription had been issued for the suspected UTI.
Results: In KAT, 397 of 6882 (6%) participant-reported hospital admissions were confirmed as relevant to the trial
knee. In REFLUX, 16 of 19 participants (84%) who appeared to have had a re-operation were confirmed as having
had one. In RECORD, 473 of 781 (61%) fractures reported by participants were confirmed as being low-trauma
fractures. In CATHETER, 429 of 830 participant-reported UTIs (52%) were confirmed as such by the GPs.
Conclusions: We used different approaches in our verification of participant-reported outcomes in clinical trials,
and we believe there is no one optimal solution. Consideration of issues such as what information is sought from
participants, the phrasing of questions, whether the medical records are a true ‘gold standard’ and costs and
benefits to the RCT may help determine the appropriate approach.
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Background
In both research and in routine health service provision,
a review of outcomes following medical intervention (in-
cluding, for example, drug treatment, surgery, psycho-
logical interventions) is important to assess the effects of
the intervention. These outcomes may include quality of
life, disease-specific symptoms, impairment, disability,
results of laboratory tests, complications of treatment
and the need for further treatment [1–3].
Within a research context, self-reporting of clinical
outcomes (for example fracture, re-operation, and hospi-
talisation) by participants is common (for example Costa
et al. [4], Ashby et al. [5]). Many reasons may explain
this, including cost and convenience for the researchers
or that participant-reported data are becoming more
widely accepted. However, little information exists on
the ‘accuracy’ of participant-reported clinical outcomes
[6], particularly in the context of clinical trials. Existing
research, nested in observational or registry-based stud-
ies, has tended to compare participant report against
reports made by medical professionals or otherwise
captured in the medical records [3, 7–9].
Previous studies have shown variable concordance
between participant report and clinical report. A review
comparing the accuracy of questionnaire data compared
to medical records in observational studies suggest the
fairly accurate recall of events such as hospitalisation
and surgery but poorer recall of, for instance, diagnostic
X-ray [7]. In a registry study comparing participant and
surgeon-reported complications following hip arthro-
plasty, concordance varied across different complications;
for example, for pulmonary embolism, concordance was
89% compared to 32% for bleeding [8]. Similar rates were
reported by Dushey et al. (pulmonary embolism 84%;
bleeding 37%) in a registry-based study that compared
participant- and surgeon-reported complications following
knee replacement [3]. Alazzawi et al. reported approxi-
mately 80% accuracy of participant-reported complica-
tions in a single centre study of total hip and knee
replacement. They also noted that some types of post-
discharge complications appear to be more accurately re-
ported by participants than others. For example, the need
for further surgery was accurately reported by 100% of re-
spondents, compared to 75% for myocardial infarction,
and 36% for nerve injury [9].
Following adjudication of cardiovascular events re-
ported by participants or a family member in a large
randomised controlled trial (RCT) of calcium supple-
mentation, 58% (50 of 86) of self-reported strokes and
52% (33 of 64) of self-reported myocardial infarctions
were verified from the clinical records [6].
To help address the evidence gap in relation to the ac-
curacy of participant-reported clinical outcomes within
the context of pragmatic RCTs, we report four case
studies, nested within different RCTs (termed the parent
trials and summarised in Table 1), where participant-
reported clinical outcome data were compared with
those reported by clinicians or in medical notes. Within
each case study, we present the participant-reported
clinical outcomes collected, details of the verification
process and the results of this process. Each of the verifi-
cation processes were undertaken as part of the data col-
lection component of the parent trial. We then discuss
some common themes emerging from these observations.
Case study 1 - The Knee Arthroplasty Trial (KAT) [10]
Clinical outcome data and verification
Disease-specific and general quality of life, GP prescrib-
ing data, physiotherapy and outpatient consultations
related to the trial knee and hospital admissions (for any
reason) were collected by postal questionnaires com-
pleted by participants at baseline, 3 months after surgery,
1 year after and annually thereafter to 20 years (the 13-
year follow-up was complete for all participants at the
time of data extraction). Participants were asked to pro-
vide a brief description of all hospital readmissions (al-
though the study was only interested in those relevant to
the trial knee). All participant-reported hospital readmis-
sion information was uploaded onto the trial database.
The KAT nurse coordinator reviewed all the hospital
readmissions to identify those that were potentially related
to the participant’s trial knee (participants admitted for
bilateral knee replacements nominated the most painful
knee as the one to be considered for randomisation) and
for these re-admissions, wrote to the lead surgeon/hospital
where the readmission occurred and asked for further
details. A proforma was designed and completed by the site
to capture important information (for example, was the
participant readmitted, did the participant require further
knee surgery) which allowed the readmissions to be classi-
fied as either ‘relevant’ or ‘not relevant’ to the trial knee.
Results of the verification
Of all hospital readmissions recorded by participants in
their questionnaires, only 6% (397/6882) were confirmed
as relevant (i.e., related to the trial knee). Most readmis-
sions (94%; 6436/6882) were either deemed to be not
relevant (i.e., not related to the trial knee) by the nurse
coordinator and therefore not followed up or confirmed
as not relevant by the lead surgeon/hospital where the
readmission took place. In 0.7% (49/6882) of the cases,
verification from the lead surgeon/hospital was ongoing
at the time of writing.
Case study 2: REFLUX [11]
Clinical outcome data and verification
Participants were followed up with annual postal ques-
tionnaires for a minimum of 5 years. The questionnaire
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collected information about disease-specific and generic
quality of life; reflux medication use; and any GP visits,
hospital outpatient consultations, or day and overnight
hospital admissions in the previous year; and the reasons
for these (including repeat surgery).
One of the key outcomes of the trial was reflux-related
re-operation for reflux symptoms; differentiating between
true cases of repeat surgery and other unrelated surgical
procedures was considered important. Four types of re-
operations were considered: conversion (to a different type
of wrap), reconstruction of the same wrap, reversal of the
fundoplication or repair of hiatus hernia only. From the
free text provided by participants in their questionnaires,
confirmation that surgery re-operation had taken place or
of the type of re-operation was not always possible. From
the self-reported data, we identified participants who ap-
peared to have had repeat surgery, and the Chief Investi-
gator and Lead Surgeon wrote to the surgeon at the site to
ask for further details about the surgery. We designed a
proforma to capture the relevant information, which in-
cluded (i) whether any record existed of a re-operation,
(ii) what type of hernia was involved, (iii) what type of re-
operation was undertaken, and (iv) the reasons for the re-
operation. If there was no response to the initial request, a
reminder letter was sent.
Results of the verification
From the participant self-report, we identified 19 partici-
pants who appeared to have had a re-operation. Three
of the participants were confirmed as not having had re-
peat surgery. The remaining 16 were confirmed as hav-
ing had repeat surgery, and we were able to classify the
type of repeat surgery (for example reconstruction, con-
version etc). We also confirmed that two of the partici-
pants had a third re-operation.
Case study 3: The RECORD trial [12]
Clinical outcome data and verification
Following randomisation, participants were asked to
complete postal questionnaires every 4 months until all
participants had been followed up for a minimum of 24
months. The questionnaires contained three questions
that capture the primary outcome for the trial - new low-
trauma fractures including clinical, radiologically con-
firmed, vertebral fractures (excluding those of the face and
skull). Fractures reported by participants were verified by
research nurses at the sites where possible. Furthermore,
to try to ensure as complete a dataset as possible (due to
participant dropout/non-response to postal question-
naires/admission occurring at a non-RECORD hospital), a
survey was conducted of GPs of all trial participants at the
end of follow-up to ask about further fractures. Hospital
episode statistics (HES) and Information Services Division
(ISD) data were also used in the verification process.
Results of the verification
Participants reported 781 broken bones, of which 489
were deemed potentially relevant by the trial team and
Table 1 Summary of parent trials
Trial Design and comparisons Recruitment
The Knee Arthroplasty Trial
(KAT) [10]
ISRCTN45837371
NIHR Health Technology
Assessment Programme
Partial factorial, pragmatic, multicentre RCT comparing
three aspects of knee replacements: resurfacing the patella
vs no resurfacing; mobile bearing between the tibial and
femoral components vs standard designs without a mobile
bearing; and metal-backed plate for the tibial component
vs single high-density- polyethylene component.
July 1999 to January 2003, 2352 participants
randomised:
Resurfacing patella (n = 1715)
Mobile bearing (n = 539)
Metal backing (n = 409)
345 participants randomised in more than
one comparison.
The REFLUX trial [11]
ISRCTN15517081
NIHR Health Technology
Assessment Programme
Pragmatic, multi-centre RCT to evaluate the clinical effectiveness,
cost effectiveness and safety of a policy of relatively early
laparoscopic surgery compared with continued, but optimised
medical management amongst people with gastro-oesophageal
reflux disease (with contemporaneous patient preference arms).
March 2001 to June 2004, 357 participants
randomised:
Surgery (n = 178)
Medical management (n = 179).
453 participants entered the preference arm:
Preferred surgery (n = 261)
Preferred medical management (n = 192)
The RECORD trial [12]
ISRCTN51647438
UK Medical Research Council
Factorial, pragmatic, multi-centre RCT to assess whether 800 IU
daily oral vitamin D3 and 1000 mg calcium, either alone or in
combination, were effective in prevention of secondary fractures.
January 1999 to March 2002, 5292 participants
randomised:
Vitamin D and calcium (n = 1306)
Vitamin D alone (n = 1343)
Calcium alone (n = 1311)
Placebo (n = 1332)
The CATHETER trial [13]
ISRCTN75198618
NIHR Health Technology
Assessment Programme
Pragmatic, multi-centre randomised controlled trial to evaluate
the clinical and cost effectiveness of three different types of
urethral catheters (antiseptic-coated (silver) latex catheter,
antimicrobial-impregnated (nitrofurazone) catheter or a standard
PTFE-coated latex catheter) to reduce catheter-associated urinary
tract infections (UTIs).
July 2007 to September 2010, 6394 participants
randomised and included:
Silver alloy catheter (n = 2097)
Nitrofurazone catheter (n = 2153)
PTFE catheter (n = 2144)
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were subject to verification. The other fractures that
were reported by participants were not considered rele-
vant to the primary outcome and therefore were not fur-
ther verified. Four hundred and forty-five of the 489
fractures were subsequently verified from X-ray reports
in primary and secondary care records, 28 were verified
from clinical diagnosis recorded in primary and second-
ary care records, and the 16 remaining fractures re-
ported could not be verified from primary or secondary
care sources.
Case study 4 – CATHETER [13]
Clinical outcome data and verification
The primary outcome for the RCT was the incidence of
catheter-associated urinary tract infection (CAUTI) in
the 6 weeks following randomisation. This was defined
as participant-reported symptoms of urinary tract infec-
tion (UTI) with a prescription of antibiotic for a UTI.
Data were collected via postal questionnaires and diaries
at 3 days, 1 week and 2 weeks post-catheter removal and
6 weeks post-randomisation. During the trial, the DMC
noted a higher than expected proportion of participants
reporting the primary outcome. Further investigation re-
vealed that this may have been due to uncertainty on the
part of the participant about their prescription and the
purpose of the antibiotics they received (e.g., prophylaxis
post-surgery rather than to treat a suspected UTI).
Therefore, the GPs of participants who reported a UTI
were contacted to request confirmation that an anti-
biotic prescription had been issued and that this was for
a suspected UTI.
GPs were asked to complete a proforma with informa-
tion on whether the participant had been diagnosed with
a UTI during the time they were in the trial, and
whether they had received a prescription for antibiotics
for a UTI during that time. The proforma was sent to a
named GP, with a reminder if no response was received.
Further telephone reminder calls were made from the
trial office to GPs who failed to respond to the reminder
letter. In addition, the Scottish Primary Care Research
Network and Primary Care Research Network in England
(SPCRN and PCRN, respectively) nurses were contacted
to help elicit a response or collect the required informa-
tion from non-responding GP practices.
Results of the verification
The GPs of 830 participants were contacted to verify
participant-reported UTIs. Of the GPs contacted to con-
firm participant-reported UTI and antibiotic prescrip-
tion, 429 of 830 (51.7%) confirmed the participant
information was correct, and 393 (47.3%) confirmed
there had been no UTI. Overall, the presence/absence of
UTI could not be confirmed by the GP or the GP did
not agree to provide the information for eight partici-
pants (1.0%).
Discussion
In this paper we have demonstrated different approaches
to the clinical verification of participant-reported outcomes
that have been used with varying success in our clinical tri-
als unit. We have developed the approaches to verification
on a trial-by-trial basis to accommodate the requirements
of the individual trial, the type of participant-reported clin-
ical outcome and the available resources.
The outcomes of interest have been varied and include
related hospitalisations, repeat surgery, further low-
trauma fractures and post-catheterisation UTI. Because
of the diverse nature of the trials in which our case stud-
ies were nested and the different approaches to verifica-
tion used, we did not set out to assess whether some
clinical outcomes were more accurately reported by par-
ticipants than others. However, limited data from other
studies suggest that this may be the case [6–9]. A pos-
sible reason for this may be that participants find some
outcomes easier to report than others because of the ter-
minology and language used in the questionnaire, how
familiar the participants are with the outcome or what
they are told by medical staff. For example, in the
CATHETER case study, some participants were given
prophylactic antibiotics and may have thought this was
to treat rather than to prevent an infection. We are
aware of one previous study comparing participant and
clinician reports of UTI, which showed 82 and 84%
agreement at 3 and 12months post-prostatectomy [14],
but it is not clear what question(s) participants were
asked in order to compare this data or what the clinical
definition of a UTI was. In CATHETER, participants
were asked ‘have you had a urine infection’ and ‘have
you received antibiotics for a urine infection’. The trial,
therefore, likely identified symptomatic UTIs where par-
ticipants sought treatment and prophylactic antibiotics
rather than asymptomatic microbiologically confirmed
UTIs.
A further mismatch may have occurred in the partici-
pant’s and clinical/research staff’s understanding (or
misunderstanding) of a medical term. For example, in
CATHETER, participants were asked which antibiotic
they had been prescribed, and in a number of cases, the
participant could not recall the name, or described a
drug that was either not an antibiotic or would not be
used to treat UTIs. An alternative approach may have
been to list the antibiotics used to treat UTIs and ask
the participants whether they had received any of these.
Alazzawi provide an example of four participants incor-
rectly reporting that they had a stroke when they had ex-
perienced a transient ischaemic attack (TIA) [9]. In a
population-based survey, only 29% of those reporting a
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stroke had this verified by hospital records [15]. Partici-
pants who experience a TIA may understand that they
have had ‘mini-stroke’, but not recognise that this is the
same as a TIA, so such misunderstandings are perhaps
unsurprising. Furthermore, participants may not be pro-
vided with sufficient information about a medical term
to accurately record the outcome of interest. For ex-
ample, Dushey et al. [3] noted 36.7% accuracy of
participant-reported major bleed episodes: the clinical
verification undertaken followed strict criteria, but par-
ticipants were not given any criteria as to what consti-
tuted a major bleed.
The timing by which participants are asked to report
an outcome (in relation to both the outcome itself and
in relation to the original event) may also impact on the
accuracy of their reporting. Other factors that may im-
pact on the accuracy of participant-reported clinical out-
comes is how relevant the outcome is to the participant
themselves or how much impact it has on their life. The
need for repeat surgery is likely to have a bigger impact
on the participant’s life than, for example, a urinary tract
infection.
Within this piece of work, we set out to verify the clin-
ical events that were reported by participants. Partici-
pants may, of course, have experienced relevant clinical
events that they did not report in a questionnaire. When
relying on participant-reported outcomes only, the mag-
nitude of this is not known. This may be a limitation of
the verification methodology more generally.
A further limitation (of our case studies, and previous
work in this area) is that the ‘clinical verification’ pro-
vided by medical records may not be a true gold stand-
ard. For example, the records themselves may be subject
to inaccuracies.
An alternative to verifying participant-reported out-
comes using individual patient’s medical records would
be to confirm them using routine datasets, but again
limitations may exist in such an approach. Routine data
may be subject to inaccuracies; for example, Information
Services Division (ISD) has a standard for accuracy of
routine data of 90%, and for general/acute inpatient and
day cases (SMR01) they report and accuracy of 89–94%
[16]. Possible reasons for inaccuracy of routine data in-
clude operations being miscoded (perhaps due to a lack
of clinical engagement in coding [17]) or operations be-
ing coded to the wrong participant. For certain condi-
tions, other limitations may exist in relation to using
routine data to verify participant-reported clinical out-
comes. First, insufficient information may exist to enable
one to identify which limb was involved or to identify
the specific types of operation. Second, operations carried
out privately will not be captured in routine data, which
may be particularly problematic if this constitutes a large
proportion of the operations. A third consideration relates
to potential time-lags in routine data being coded and
made available to researchers, and in the approvals
process to access routine data for research purposes.
Fourth, participants may not have given consent for use of
routine data at the outset of the trial. Finally, some out-
comes are not routinely captured in national datasets. For
example, for the CATHETER outcome (UTI), no national
register exists, and although general national prescribing
data could be used to provide information about antibiotic
prescriptions, this information could not be linked to indi-
viduals. Although routine data were available for KAT and
data about all participants were requested from GPs for
RECORD, in this paper, we did not attempt to validate
these sources.
Considering that inaccuracies may exist in both
participant-reported clinical outcomes and in data cap-
tured in medical records, decisions have to be made in
terms of which source to treat as ‘correct’. In the four
case studies presented here, different approaches were
taken. In KAT [10] and REFLUX [11], the information
from the clinician (GP or surgeon) was considered to be
the ‘correct’ information, and unless the event was veri-
fied by the GP or surgeon, it was not included in the
analysis. In RECORD [12], clinical verification of frac-
tures reported by participants was sought (from the
recruiting site, GP and/or central data sources). Frac-
tures that could not be confirmed (n = 16) were not in-
cluded in the main analysis. In CATHETER [13], where
GP information was received, it was regarded as the de-
finitive data. However, in the few (eight of 830 partici-
pants) of participant-reported UTIs that could not be
confirmed by the GP (for example, no response was re-
ceived from the GP, or the participant was no longer
registered with the GP practice), the researchers used al-
ternative sources (i.e., responses to other questions
within the questionnaire) to verify the data. Therefore,
before a process to verify participant-reported clinical
outcomes is undertaken, strategies to deal with mis-
matches in data should be considered and documented.
The potential benefit of verification of participant-
reported clinical outcomes is difficult to quantify, and
again, such quantification is not something we set out to
do in this paper. Advantages may exist in terms of the
external generalisability of the results to the population,
which can make the results appear more relevant to cli-
nicians practicing in that area. Equally, there may be
merit if there are particular safety concerns where accur-
ate reporting is essential. However, less impact on the
comparison of interventions is possible, particularly in
studies where the participant is blinded to the interven-
tion and therefore less likely to be biased by knowledge
of their treatment allocation. Thus, greater benefit may
exist in clinical verification of participant-reported out-
comes in studies that are not blinded (where participants
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may have preconceptions about the intervention they
have had). Similarly, if the outcome (and particularly any
misclassification of outcome) is not equally distributed
between arms of the parent trial, the benefit of verifica-
tion may be greater.
Whilst the potential benefit may be hard to quantify,
the costs involved in any approach to verification should
be carefully considered. Of the 6882 clinical outcomes
reported in participant questionnaires (KAT Trial), only
approximately 6% were confirmed as being relevant (i.e.,
related to the trial knee) and included in the statistical
analysis [10]. In RECORD, where they used three ques-
tions to capture the primary outcome (‘broken any
bones’, ‘how did you break’ and ‘which bone(s)’) the trial
team were better able to identify which reports were po-
tentially relevant and should be subject to further verifi-
cation [12]. Therefore, refining the question asked of
KAT participants, i.e., asking the participants to report
knee-related hospital readmissions only or ask a series of
questions to capture additional/relevant information,
may increase the proportion of events confirmed as rele-
vant and reduce the time involved in coding and/or veri-
fying those later identified as not relevant. Checking
single cases against hospital or primary care records may
simply involve a time-cost for the trial team and the
clinical staff, which will be variable contingent on the
number of cases being checked. For example, in RE-
FLUX [11], only 19 surgeons were contacted for further
information, compared to CATHETER [13], where the
GPs of more than 800 participants had to be contacted.
To facilitate the workload in CATHETER, a full-time
member of staff was employed whose main duty to man-
age the process of collecting and processing the resulting
data over a 3- to 6-month period. Both time and finan-
cial costs are associated with obtaining routine data and
linking this to trial cohorts.
Recommendations for practice
Our primary recommendation is that, during the plan-
ning phase of a trial, careful consideration be given not
only to which participant-reported clinical outcomes
should be collected and how these will be collected but
also to whether any verification of these should be
undertaken. The decisions reached are very likely to vary
on a trial-by-trial basis; it is our opinion that there is no
optimal, ‘one size fits all’ solution. However, making de-
cisions about any clinical verification of participant-
reported outcomes at the outset of the study will help
ensure that any costs associated with verification are
covered, that the trial time-line includes adequate time
for collection and verification of outcomes, and that the
consent sought from participants to allow any verifica-
tion is sufficient. Furthermore, we recommend that con-
sideration be given to how any discrepancies in outcome
identified during the verification process will be ad-
dressed (for example whether unverified outcomes will
be included in the analysis or not).
If trial participants are being asked to report clinical
outcomes as part of a questionnaire, the use of appropri-
ate language is important, so the participants can accur-
ately respond about the clinical information that is being
requested from them. The use of very ‘medical’ terms
may be inappropriate. Careful piloting of such questions
may help avoid misinterpretation, confusion or inaccur-
ate responses.
Recommendations for future research
Further reports on the approaches to and the impacts of
clinical verification of participant-reported outcomes will
help inform researchers. More formal cost-benefit type
analyses, considering both the impact and the cost of
verification, would further inform decisions about the
relative value of verification in different settings.
Conclusion
We have described a number of approaches to the clin-
ical verification of participant-reported outcomes, and
some of the issues that trialists may wish to consider
when deciding whether such verification is necessary in
a specific trial, and if so, what approach to this may be
appropriate. We believe that there is no one optimal
solution but that consideration of the issues presented
here will help inform decisions made in future trials.
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